Inactive Instrument

Misonix, Inc.

Equities

MSON

US6048711039

Medical Equipment, Supplies & Distribution

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Misonix, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Misonix, Inc.(NasdaqGM:MSON) dropped from S&P TMI Index CI
Misonix, Inc.(NasdaqGM:MSON) dropped from S&P Global BMI Index CI
Misonix, Inc.(NasdaqGM:MON) dropped from NASDAQ Composite Index CI
Bioventus Inc. completed the acquisition of Misonix, Inc. from Stavros G. Vizirgianakis, SV Life Sciences Fund VI, L.P. and Sv Life Sciences Fund VI Strategic Partners, L.P., funds managed by SV Health Investors, LLC, 1315 Capital, LLC and others. CI
Misonix : Q4 Net Loss Narrows, Revenue Surges MT
Misonix : Earnings Flash (MSON) MISONIX Posts Q4 Revenue $19.7M MT
Misonix, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2021 CI
Misonix, Inc. Announces Nonrenewal of Allan Staley as President and Named Executive Officer CI
MISONIX : BTIG Downgrades Misonix to Neutral From Buy MT
Misonix : Bioventus to Acquire Misonix in Cash-and-Stock Deal Valued at $518 Million MT
NASDAQ 100 : Top Midday Gainers MT
MISONIX : Craig-Hallum Downgrades Misonix to Hold From Buy; Price Target is $28 MT
MISONIX : Canaccord Genuity Downgrades Misonix to Hold From Buy; Price Target is $28 MT
Transcript : Bioventus Inc., Misonix, Inc. - M&A Call
Misonix, Inc. Reported Revenue Results for the Fiscal Fourth Quarter and Full Year 2021 CI
Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. from Stavros G. Vizirgianakis, SV Life Sciences Fund VI, L.P. and Sv Life Sciences Fund VI Strategic Partners, L.P., funds managed by SV Health Investors, LLC, 1315 Capital, LLC and others for approximately $500 million. CI
Transcript : Misonix, Inc. Presents at UBS Global Healthcare Virtual Conference 2021, May-25-2021 05:00 PM
Misonix, Inc. Announces Board Changes CI
Transcript : Misonix, Inc., Q3 2021 Earnings Call, May 06, 2021
Misonix : Earnings Flash (MSON) MISONIX Reports Q3 Revenue $18.3M, vs. Street Est of $18M MT
Misonix, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
Misonix, Inc. Provides Earnings Guidance for the Year of 2021 CI
Misonix : Files Shelf for Up to $100 Million in Securities MT
Misonix : Receives Regulatory Approval to Sell neXus in Canada; Shares Rise Early MT
Chart Misonix, Inc.
More charts
Misonix, Inc. (Misonix), is a medical devices company. The Company is engaged in designing, manufacturing and marketing of minimally invasive therapeutic ultrasonic medical devices. Its products include BoneScalpel Surgical System (BoneScalpel), SonicOne Wound Cleansing and Debridement System (SonicOne) and SonaStar Surgical Aspirator (SonaStar). BoneScalpel is used for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue. SonaStar is used to emulsify and remove soft and hard tumors, primarily in the neuro and general surgery field. SonicOne offers tissue specific debridement and cleansing of wounds and burns for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. The Company's products are nexus, BoneScalpel, SonaStar, SonicOne, TheraSkin and Therion.
More about the company
  1. Stock
  2. Equities
  3. Stock Misonix, Inc. - Nasdaq
  4. News Misonix, Inc.
  5. Misonix : Canaccord Genuity Downgrades Misonix to Hold From Buy; Price Target is $28